6CM
VYGR icon

683 Capital Management’s Voyager Therapeutics VYGR Stock Holding History

683 Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,000
Closed -$177K – 254
2023
Q1 		$177K Sell
23,000
-8,388
-27% -$66.7K 0.01% 174
2022
Q4 		$191K Buy
+31,388
New +$178K 0.02% 173

Other funds holding VYGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

683 Capital Management's VYGR Position: Q2 2023 in Review

683 Capital Management sold out of Voyager Therapeutics (VYGR) in Q2 2023, closing a stake of 23,000 shares — an estimated $177K sold.

683 Capital Management first reported a position in VYGR in Q4 2022 and held it in 2 quarters. The position peaked at $191K in Q4 2022. 106 funds tracked by Wall St. Rank hold VYGR as of Q2 2023.

  • 683 Capital Management reported no remaining Voyager Therapeutics position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 23,000 Voyager Therapeutics shares in Q2 2023, an estimated $177K.
  • 683 Capital Management first reported a position in Voyager Therapeutics in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's Voyager Therapeutics position peaked at $191K in Q4 2022.
  • 106 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.